Advanced Right-sided Colon CancerMARCHNCT06986538
Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance
A study testing Clearance with the left side of the SMV as the medial boundary and Clearance with the left side of the SMA as the medial boundary in people with Advanced Right-sided Colon Cancer and the Extent of Lymph Node Dissection, run by Sixth Affiliated Hospital, Sun Yat-sen University at 26 sites in China.
Trial summary
This is a prospective multicenter randomized controlled clinical study to explore the extent of lymph node dissection in progressive right hemicolon cancer and to elucidate the pattern of lymphatic drainage in the right hemicolon. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection
- What is being tested?
- Clearance with the left side of the SMV as the medial boundary and Clearance with the left side of the SMA as the medial boundary
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,064 participants
- Where
- 26 sitesChina
- Study dates
- 1 Jun 2025to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: 18-75 years
- Preoperative pathologic confirmation of adenocarcinoma
- Tumor located in the region from the ileocecal valve to the right one-third of the transverse colon
- American Society of Anesthesiologists (ASA) physical status classification I to III
- Patients who have not received preoperative radiotherapy, chemotherapy, or immunotherapy
- Preoperative imaging staging cT4N0M0 or cT3-4N+M0
- Willing to participate in the study and sign the informed consent form
Who cannot join
- Past medical history of malignant tumor
- Patients with multiple primary tumors
- Patients with a history of inflammatory bowel disease or familial adenomatous polyposis
- Patients with distant metastasis
- Pregnant or breastfeeding women
- History of other previous major abdominal surgery
- Patients requiring emergency surgery (including tumor perforation, obstruction, hemorrhage, etc.)
- Those with other clinical and laboratory conditions deemed by the investigator to be inappropriate for participation in the trial
Trial locations and contacts
26 sites in 1 country. Contact the study team or a site near you to ask about taking part.
26 sites in 1 country
China26 sites
Cancer Hospital, Chinese Academyof Medical Sciences
Beijing, Beijing Municipality, 100021
Haitao Zhou, +8613381167333, htzzz0313@163.com
Peking University People's Hospital
Beijing, Beijing Municipality, 100044
Zhanlong Shen, +8613810230190, shenzhanlong@pkuph.edu.cn
China-Japan Union Hospital of Jilin University
Changchun, Jilin, 130033
Zhongshi Xie, +8613944108332, xiezs@jlu.edu.cn
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041
Wenjian Meng, +8618980606727, mengwenjian@126.com
Fujian Medical University Affiliated Union Hospital
Fuzhou, Fujian, 350001
Ying Huang, +8613365910923, hy9033sy@sina.com
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510030
Deqing Wu, +8613902301120, 13902301120@139.com
the First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080
Sun Yat-sen University Cancer Hospital
Guangzhou, Guangdong, 510110
Junzhong Lin, +8613802446666, linjzh@sysucc.org.cn
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, 510405
Wenjun Xiong, +8615920553177, xiongwj1988@163.com
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515
Yanan Wang, +8615018753181, wyn8116@163.com
Department of Coloretcal Surgery, the Sixth Affiliated Hospital of Sun Yat-sen University,
Guangzhou, Guangdong, 510655
Guizhou Cancer Hospital
Guiyang, Guizhou, 550004
Zejun Wang, +8613639075460, 162234839@qq.com
Qilu Hospital of Shandong University
Jinan, Shandong, 250000
Yanlei Wang, +8618560085128, wangyanleinmg@126.com
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
Wan Li, +8613317977082, 55002462@ncepu.edu.cn
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
Jun Huang, +8613870972177, huangjun@mail.shufe.edu.cn
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Nanning, Guangxi, 530023
Qingyuan People's Hospital
Qingyuan, Guangdong, 511500
Canfeng Cai, +8613435298705, thoes007@126.com
Cancer Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032
Dawei Li, +8613774201693, li_dawei@fudan.edu.cn
Shanghai Tenth People's Hospita
Shanghai, Shanghai Municipality, 200072
Zhongchen Liu, +8618917688565, liuzhongchen10th@163.com
Changhai Hospitalof Naval Medical University
Shanghai, Shanghai Municipality, 200433
Hao Wang, +8613901883868, wanghaohh@vip.126.com
Yuebei People's Hospital
Shaoguan, Guangdong, 512000
Jiajun Lai, +8613826329222, 13826329222@163.com
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110000
The First Affiliated Hospital of WenzhouMedical University
Wenzhou, Zhejiang, 325005
Shaotang Li, +8618066285566, lishaotang163@163.com
Shaanxi ProvincialPeople's Hospital
Xian, Shanxi, 710068
Ruiting Liu, +8613008428826, fgpeter82Dr@163.com
Zhaoqing First People's Hospital
Zhaoqing, Guangdong, 526020
Qing Zhang, +8613929866162, 13701989836@163.com
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052
Junhong Hu, +8618337178698, happyjunhong@163.com
About this study
Official title: A Multicenter Randomized Controlled Study of the Extent of Lymph Node Dissection for Advanced Right-sided Colon Cancer
This is a prospective multicenter randomized controlled clinical study to explore the extent of lymph node dissection in progressive right hemicolon cancer and to elucidate the pattern of lymphatic drainage in the right hemicolon.
- Being tested
- Clearance with the left side of the SMV as the medial boundary, Clearance with the left side of the SMA as the medial boundary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clearance with the left side of the SMV as the medial boundaryProcedure or surgery
Undergo radical resection for right colon cancer with the left side of the SMV as the medial boundary
Clearance with the left side of the SMA as the medial boundaryProcedure or surgery
Undergo radical resection for right colon cancer with the left side of the SMA as the medial boundary
| Study group | Role | What they receive |
|---|---|---|
| SMV group | Active comparator | Not described Receives: Procedure: Clearance with the left side of the SMV as the medial boundary |
| SMA group | Experimental | Not described Receives: Procedure: Clearance with the left side of the SMA as the medial boundary |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease-Free Survival
It is defined as the proportion of patients from the start of randomization to the end of the third year without any of the following events: disease progression, local recurrence, distant metastasis, second primary colorectal cancer, or death from any cause.
Measured: The third postoperative year
Secondary outcomes (1)
overall survival
The time from randomization to death from any cause.
Measured: The third postoperative year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2025
- Study start1 Jun 2025 (estimated)
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Right-sided Colon CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 1,064 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06986538
- Sponsor's protocol ID
- MARCH
- Acronym
- MARCH
- Status last verified
- May 2025
- First submitted
- 15 Apr 2025
- Last updated
- 23 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Randomized Controlled Study of the Extent of Lymph Node Dissection for Advanced Right-sided Colon Cancer
- ClinicalTrials.gov ID
- NCT06986538
- Acronym / sponsor ID
- MARCH / MARCH
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,064 participants (estimated)
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (estimated)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 23 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective multicenter randomized controlled clinical study to explore the extent of lymph node dissection in progressive right hemicolon cancer and to elucidate the pattern of lymphatic drainage in the right hemicolon.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SMV group | Active comparator | Procedure: Clearance with the left side of the SMV as the medial boundary |
| SMA group | Experimental | Procedure: Clearance with the left side of the SMA as the medial boundary |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age: 18-75 years
- Preoperative pathologic confirmation of adenocarcinoma
- Tumor located in the region from the ileocecal valve to the right one-third of the transverse colon
- American Society of Anesthesiologists (ASA) physical status classification I to III
- Patients who have not received preoperative radiotherapy, chemotherapy, or immunotherapy
Key exclusion criteria (8 listed)
- Past medical history of malignant tumor
- Patients with multiple primary tumors
- Patients with a history of inflammatory bowel disease or familial adenomatous polyposis
- Patients with distant metastasis
- Pregnant or breastfeeding women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clearance with the left side of the SMV as the medial boundaryUndergo radical resection for right colon cancer with the left side of the SMV as the medial boundary | Procedure or surgery | SMV group |
| Clearance with the left side of the SMA as the medial boundaryUndergo radical resection for right colon cancer with the left side of the SMA as the medial boundary | Procedure or surgery | SMA group |
Primary outcome
Disease-Free Survival
Time frame: The third postoperative year
It is defined as the proportion of patients from the start of randomization to the end of the third year without any of the following events: disease progression, local recurrence, distant metastasis, second primary colorectal cancer, or death from any cause.
1 secondary outcome
overall survival
Time frame: The third postoperative year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2025.
- Individual participant dataSharing planned: No
Related trials for Advanced Right-sided Colon Cancer
RecruitingPhase 2
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
Colorectal Cancer (CRC)
RecruitingObservational study
Mesogastrium Metastasis in Colon Cancer
Colon Cancer
Not yet recruitingPhase 4
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
Colorectal Cancer
RecruitingPhase 2
Fluorescence Lymph Node Mapping for Colon Cancer Surgery
Right Hemicolectomy
Active, not recruitingPhase 3
Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer
Colon Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
26 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clearance with the left side of the SMV as the medial boundary and Clearance with the left side of the SMA as the medial boundary in people with Advanced Right-sided Colon Cancer and the Extent of Lymph Node Dissection, run by Sixth Affiliated Hospital, Sun Yat-sen University at 26 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 26 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiaqi Ren (+8619120517547, 19120517547@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease-Free Survival (time frame: The third postoperative year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2025.